Pharma’s R&D, commercial approach shifts amid global policy evolution

Neutral

AI Analysis

Summary

A survey of 175 pharma executives reveals shifting R&D and commercial strategies, with pharmaceutical companies increasingly reluctant to launch in lower-value markets and focusing more on real-world evidence (RWE).

Importance:2/10

Sentiment:

0.00

industry_trendsR&D_strategycommercial_strategymarket_accessregulatory_policyRWE

Read the original article

Published by Clinical Trials Arena on September 9, 2026 3:36 PM

Read Original